Katherine Moxley, MD
Gynecologic Oncology · Tulsa, OKNPI 1548308448
Payments from drug & device makers
Across 143 payments — averaging $2925.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$246K
- Takeda Pharmaceuticals U.S.A., Inc.$124K
- GSK$21K
- Intuitive Surgical$8K
- Tesaro, Inc.$8K
- AstraZeneca$6K
- plus $6K from 10 others
Across 4 payments — averaging $472.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1K
- F. Hoffmann-la Roche AG$619
What the payments were for
- Consulting fees$16,85038%
- Speaking & faculty fees$16,12536%
- Travel & lodging$5,40712%
- Food & beverage$1,2353%
- Education$4,59310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 32 | $245,918 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $124,012 |
| GSK | 18 | $20,587 |
| Intuitive Surgical | 26 | $8,445 |
| Tesaro, Inc. | 7 | $7,519 |
| AstraZeneca | 3 | $5,509 |
| Incyte Corporation | 20 | $2,111 |
| E.r. Squibb & Sons, L.L.C. | 1 | $2,098 |
| AVEO Pharmaceuticals, Inc. | 1 | $1,000 |
| AbbVie | 3 | $859 |
| Clovis Oncology, Inc. | 4 | $93 |
| Daiichi Sankyo Inc. | 3 | $62 |
| Seagen Inc. | 1 | $43 |
| Novartis | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEJULA$16,064
- JEMPERLI$11,718
- DAVINCI XI$4,500
- Da Vinci Surgical System$3,672
- Enhertu$3,425
- FOTIVDA$1,000
- Elahere$840
How this compares
$418,332 in reported general payments places this provider in the 70th percentile of 21 gynecologic oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 19 | $12,705 |
| Estradiol | 43 | $1,973 |
| Megestrol Acetate | 22 | $1,020 |
| Ondansetron Hcl | 38 | $531 |
| Prochlorperazine Maleate | 39 | $412 |
| Letrozole | 19 | $401 |
| Oxycodone Hcl | 41 | $325 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 21 | $235 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $231 |
| Nystatin | 15 | $217 |
| Celecoxib | 14 | $154 |
| Levofloxacin | 27 | $142 |
| Ondansetron OdtOndansetron | 14 | $122 |
| Methocarbamol | 12 | $94 |
| Fluconazole | 14 | $74 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Tulsa
- Michael GoldTulsa$2.8M
- Daron StreetTulsa$278K
- Alfred JenkinsTulsa$994
- Debra RichardsonOklahoma City$8M
- Robert MannelOklahoma City$5.8M
- Lauren DockeryOklahoma City$3M
- Christina WashingtonOklahoma City$1.6M
- Camille JacksonOklahoma City$886K
- Tara CastellanoOklahoma City$68K
- Joan WalkerOklahoma City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.